The estimated Net Worth of Alexis Borisy is at least $5.83 Million dollars as of 19 June 2020. Mr. Borisy owns over 1,312 units of Blueprint Medicines Corp stock worth over $5,385,590 and over the last 9 years he sold BPMC stock worth over $0. In addition, he makes $440,643 as Director at Blueprint Medicines Corp.
Alexis has made over 2 trades of the Blueprint Medicines Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,312 units of BPMC stock worth $113,567 on 19 June 2020.
The largest trade he's ever made was exercising 21,818 units of Blueprint Medicines Corp stock on 27 June 2019 worth over $715,194. On average, Alexis trades about 526 units every 8 days since 2015. As of 19 June 2020 he still owns at least 62,218 units of Blueprint Medicines Corp stock.
You can see the complete history of Mr. Borisy stock trades at the bottom of the page.
Alexis A. Borisy serves as Director of the Company. Mr. Borisy has served as a member of our board of directors since April 2011. Mr. Borisy co-founded Blueprint Medicines and served as our interim chief executive officer from May 2013 through July 2014. Since 2010, Mr. Borisy has been a partner at Third Rock Ventures, or Third Rock, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Mr. Borisy currently serves on the board of directors for Magenta Therapeutics, Inc. In addition, Mr. Borisy currently serves on the board of directors of Revolution Medicines, Inc., a privately held biopharmaceutical company, and as executive chairman on the board of directors of the following privately held biopharmaceutical companies: Celsius Therapeutics, Inc., Relay Therapeutics, Inc. and Tango Therapeutics, Inc. From November 2013 to March 2018, Mr. Borisy served as a member of the board of directors of Editas Medicine, Inc. From 2007 to 2012, Mr. Borisy served as chairman of FORMA Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing medicines in cancer and other genetically-driven diseases. Mr. Borisy co-founded Foundation Medicine, Inc., or Foundation Medicine, where he served as its interim chief executive officer from 2009 to 2011 and has served as a member of its board of directors since 2009, including as chairman of Foundation Medicine’s board of directors from 2011 to February 2017. In 2000, Mr. Borisy founded CombinatoRx, Inc. and served as its chief executive officer and on its board of directors from 2000 to 2009. Mr. Borisy received an A.B. in chemistry from the University of Chicago and an A.M. from Harvard University.
As the Director of Blueprint Medicines Corp, the total compensation of Alexis Borisy at Blueprint Medicines Corp is $440,643. There are 22 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
Alexis Borisy is 48, he's been the Director of Blueprint Medicines Corp since 2014. There are 22 older and 5 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
Alexis's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DR, REDWOOD CITY, CA, 94063.
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr, and Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: